Showing results (71-80 of 450) with videos related to
Sort By:
Pageof 45
British Journal of Cancer|February 1, 1980
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogsR A White, P WorkmanBritish Journal of Cancer|May 1, 1983
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in miceF Y Lee, P WorkmanBritish Journal of Cancer|July 1, 1983
Chemosensitization by lipophilic nitroimidazolesP R Twentyman, P WorkmanCancer Chemotherapy and Pharmacology|January 1, 1981
Structure-pharmacokinetic relationships for misonidazole analogues in miceP Workman, J M BrownInternational Journal of Radiation Oncology, Biology, Physics|September 1, 1984
Nitroimidazoles as modifiers of nitrosourea pharmacokineticsF Y Lee, P WorkmanThe British Journal of Radiology|December 2, 2004
The role of functional and molecular imaging in cancer drug discovery and developmentB M Seddon, P WorkmanBiochemical Pharmacology|January 22, 1992
Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cellsR J Riley, P WorkmanCancer Chemotherapy and Pharmacology|January 1, 1986
Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustardsF Y Lee, P WorkmanBritish Journal of Cancer|January 1, 1985
Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNUF Y Lee, P WorkmanEuropean Journal of Cancer (Oxford, England : 1990)|March 11, 2000
Discovering novel chemotherapeutic drugs for the third millenniumM D Garrett, P WorkmanPageof 45